Musculoskeletal companies develop therapies, diagnostics and technologies for conditions affecting bones, joints, muscles, tendons and connective tissues. Their work supports pain management, tissue repair, mobility and the treatment of chronic and degenerative disease.
This category includes companies working on:
Browse 29 UK musculoskeletal companies below.
Colorimetric assay kits for extracellular matrix analysis and quantification
Biocolor is a Northern Ireland manufacturer of dye-based, colorimetric assay kits for the quantitative analysis of extracellular matrix biomolecules. Its product range covers collagen, elastin, sulfated glycosaminoglycans, proteoglycans, hyaluronic acid, and apoptosis, using a simple dye-binding method compatible with…
Mitochondrial sulfide-donor therapeutics for obesity and myopathies
MitoRx Therapeutics is a company developing first-in-class small molecule therapeutics that target mitochondrial sulfide signalling, a mechanism implicated in metabolic dysfunction and muscle disease. Its lead programme is an injectable mitochondria-targeted sulfide donor designed to achieve fat loss without lean mass…
Tissue-targeted gene and RNA delivery platforms for rare and neurological disease
Dawn Therapeutics is a pre-clinical biotechnology company developing precision delivery platforms for genetic medicines targeting the central nervous system, cartilage, and bone. Its transferrin receptor-guided system is designed to cross the blood-brain barrier and deliver RNA or DNA payloads to neuronal tissues,…
Perfluorocarbon oxygen carrier therapeutic and MRI imaging agent for acute stroke
Aurum Biosciences is a Scottish clinical-stage biopharmaceutical company developing ABL-101, a perfluorocarbon-based oxygen carrier that bypasses arterial clots to deliver oxygen to ischaemic tissue via collateral vessels. The lead indication is acute ischaemic stroke, with ABL-101 having completed Phase 1 and 2a…
Immunometabolism drugs for autoimmune and inflammatory diseases
Istesso is a drug discovery and development company working in immunometabolism, developing oral small molecule therapies that reprogram cellular metabolism to treat autoimmune and inflammatory conditions. Its lead candidate is a first-in-class metabolic reprogramming agent for rheumatoid arthritis with a dual…
TSG-6 protein therapeutics for inflammatory and degenerative disease
Link Biologics is a preclinical-stage biotechnology company developing protein therapeutics based on TSG-6, an endogenous human protein with anti-inflammatory and tissue-protective properties. Spun out from the University of Manchester in 2021, the company is advancing its lead asset, Link_TSG6, across programmes in…
RNA therapeutics targeting cellular senescence and age-related disease
Senisca is a preclinical-stage biotechnology company developing oligonucleotide and small molecule therapeutics that reverse cellular senescence by restoring RNA splicing factor activity. Its platform targets the molecular mechanisms of cellular ageing and has broad applicability across multiple age-related diseases.…
Controlled-release orthobiologics for spinal fusion and bone repair
Locate Bio is a clinical-stage biotechnology company developing a portfolio of orthobiologic products for musculoskeletal surgery. Its proprietary Programmed Drug Release platform encapsulates recombinant proteins within biodegradable polymer scaffolds to enable controlled, extended-release delivery. Lead product…
DNA-based gene therapy platform for intercellular therapeutic gene delivery
Bitrobius Genetics is a UK biotech developing a novel DNA-based gene therapy platform technology designed to deliver functional copies of mutated genes to cells within a target tissue or organ. Its platform is based on the principle of DNA replication and intercellular transmission, aiming to achieve broad tissue…
CBD-based licensed medicines for chronic inflammatory pain
Ananda Pharma is an AQSE-listed UK biotechnology company developing pharmaceutical-grade cannabidiol formulations as licensed medicines for chronic inflammatory pain conditions. The company focuses on essentially THC-free CBD products manufactured to UK pharmaceutical standards, targeting conditions including…
MicroRNA therapeutics for tendon and musculoskeletal disease
Causeway Therapeutics is a clinical-stage biotechnology company developing first-in-class microRNA therapies for musculoskeletal and age-related conditions. Its lead asset TenoMiR (CWT-001) is a synthetic miR-29a mimic delivered by single intratendinous injection that promotes collagen remodelling and tendon repair.…
Injectable biomaterial gel to treat degenerative disc disease
Orthoson is a medtech company developing micro-invasive injectable treatments for chronic back pain caused by degenerative disc disease. Its lead product, a patented pNIPAM-DMAc co-polymer hydrogel, is designed to be injected into the intervertebral disc, where it gels in-situ to restore the mechanical and biological…
Clinical-stage rare disease biotech acquiring deprioritised pharma assets
Mereo BioPharma is a clinical-stage biopharmaceutical company focused on developing treatments for rare diseases. Founded in 2015, its business model centres on acquiring clinical-stage programmes deprioritised by large pharmaceutical companies and advancing them through further development. Lead programmes include…
Contract development and manufacture of nanofibrous biomaterials for medical devices
The Electrospinning Company designs, develops, and manufactures nanofibrous biomaterials for implantable medical devices and regenerative medicine applications. Using electrospinning technology, the company produces four proprietary membrane platforms: resorbable Mimetix, permanent Kalyptix, biosynthetic Symatix, and…
Extracellular vesicle platform for consistent, scalable regenerative therapeutics
Mesenbio is a preclinical-stage biopharmaceutical company developing a cell line platform that produces a consistent, scalable supply of therapeutic extracellular vesicles, addressing a key bottleneck limiting this treatment class. The company's cells generate naturally bioactive vesicles with combined…
AI-driven target discovery from human tissue omics
Relation is a platform biotechnology company integrating machine learning with single-cell and spatial multi-omics data derived directly from patient tissue to discover and validate novel drug targets. Its initial research focus is bone biology, with a proprietary observational study generating deeply characterised…
Biologic therapy for osteoarthritis pain
Levicept is a clinical-stage biotechnology company developing a once-monthly biologic treatment for osteoarthritis pain. Its receptor fusion protein is designed to rebalance neurotrophin signalling in affected joints, potentially providing a non-opioid treatment option. The company has completed a Phase II study…
Calcium-compound bone and antibiotic-carrier devices for surgical infection management
Biocomposites is a UK-based medical device company that engineers, manufactures and markets calcium compound devices for infection management in bone and soft tissue. Its product range includes bone graft substitutes and antibiotic-carrier matrices used to deliver local antibiotic treatment during surgery, serving…
Medical imaging CRO and AI platform for clinical trials
Image Analysis Group is a specialist imaging contract research organisation serving biotech and pharmaceutical companies across all clinical trial phases. The company designs and executes imaging-based efficacy and safety endpoints, provides centralised independent radiological review, and delivers quantitative image…
Antimicrobial and biocompatible surface coatings for orthopaedic implants
Accentus Medical is a surface engineering company developing and applying biocompatible and antimicrobial coatings for implantable medical devices, particularly orthopaedic implants. Its technologies include plasma-sprayed titanium and hydroxyapatite coatings that support bone integration, and silver-ion surface…